ABILITA BIO NEWS
December 18, 2024
Abilita Therapeutics and Orion Announce Research Collaboration to Develop Next-Generation Antibody Therapeutics in the Areas of Oncology and Pain
– Collaboration leverages Abilita’s pioneering EMP™ antibody discovery platform for challenging multi-span membrane protein (MMP) targets
– Orion has an option to license an undisclosed Abilita discovery program and select two additional MMP targets for drug discovery over the collaboration period
– Abilita has the potential to earn up to $785 million plus royalties on commercial sales
Full Press Release
June 1, 2023
Abilita Bio changes name to Abilita Therapeutics and appoints Joel Edwards as chief business officer
Name change to Abilita Therapeutics reflects the company’s focus and newly established capabilities to build an internal pipeline of first- and best-in-class therapeutics.
Abilita Therapeutics strengthens leadership team by appointing Joel Edwards as chief business officer to advance corporate strategy and partnering efforts.
Full Press Release
Press Release direct link
May 9, 2023
Abilita Bio to showcase Enabled Membrane Protein technologies at PEGS Boston conference
On the heels of a $7.5m financing round, the company will present its breakthrough platform technologies that are empowering the development of membrane protein-targeted treatments.
Full Press Release
February 21, 2023
Abilita Bio secures $7.5 million in equity financing from Two Bear Capital
Funding will Propel Abilita Bio’s Preclinical Therapeutic Programs and Accelerate the Company’s Overall Growth.
Full Press Release
Press Release direct link
March 23, 2022
Abilita Bio selected as one of San Diego’s ‘Cool Companies’ 2022
Abilita Bio will also participate as a ‘Cool Company’ to the first ‘San Diego Innovation Day’ event, organized by CONNECT on April 28 at Petko Park, San Diego.
Link to the event
Link to the ‘Cool Company’ site
February 23, 2022
Abilita Bio Appoints Dan Bradbury to its Newly Formed Board of Directors
Abilita Bio, Inc., today announced the appointment of Daniel M. Bradbury to its Board of Directors. Mr. Bradbury is a seasoned biotech executive and business strategist with a formidable track record of building successful biotech companies. His guidance will be key to growing the leadership team, crafting our approach, and building a solid clinical development plan.
Full press release
PR Newswire link
August 24, 2021
Abveris and Abilita Bio Announce a Discovery Collaboration to Develop Therapeutics for Challenging Membrane Protein Targets
The research collaboration will leverage synergies between the Abilita Bio EMP™ and Abveris DiversimAb™ platforms to identify novel therapeutic antibodies that target historically intractable GPCRs for the treatment of cancer
January 9, 2020
Abilita Bio Announces Business Growth and Key Developments
Shift to discovery of proprietary programs facilitated by increased resources, infrastructure and capabilities
Abilita Bio, Inc. today announced a series of corporate updates that includes an expansion of scientific scope, personnel, and infrastructure.
Full press release
GlobeNewswire link
May 20, 2019
Tom Boone joins Abilita Bio’s Scientific Advisory Board
Abilita Bio today announced the appointment of Tom Boone, a world-renowned expert in biologics discovery and development, to their Scientific Advisory Board.
Full Release
June 3-6, 2019
Abilita Bio will be an exhibitor at the 2019 BIO Convention in Philadelphia
Abilita Bio will be participating in the BIO Convention exhibition and One-on-One Partnering™ program, taking place at the Pennsylvania Convention Center in Philadelphia, PA. Meet with us at our exhibit kiosk IZ-21 within the NIH Innovation Zone (Booth #4270).
